Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

What you need to know about the coronavirus right now

Published 25/01/2021, 05:33 pm

Jan 25 (Reuters) - Here's what you need to know about the coronavirus right now:

First New Zealand case in months

New Zealand on Monday confirmed its first case of COVID-19 in the community in months in a 56-year-old woman, but said close contacts of the recently returned traveller had so far tested negative.

The woman, who returned to New Zealand on Dec. 30, had tested positive for the South African strain of the virus after leaving a two-week mandatory quarantine where she had twice tested negative, COVID-19 response minister Chris Hipkins said.

No other community cases had been reported since the woman's case was disclosed on Sunday and authorities said the source of the infection was probably a fellow returnee at the quarantine facility. Authorities were looking at whether the virus was spreading through the ventilation and air-conditioning systems in these facilities, Hipkins said. asymptomatic patients drive rise in China's daily cases

China reported a climb in new COVID-19 cases driven by a spike in infections among previously symptomless patients in northeastern Jilin province, official data showed on Monday.

Of the 117 new local infections, Jilin accounted for 67 cases - all but three of whom were previously asymptomatic patients who were reclassified as confirmed cases after developing symptoms.

Authorities have rolled out a combination of measures including home quarantine of millions of people, travel curbs, mass testing and screening. approves Pfizer (NYSE:PFE) vaccine, warns of limited global AstraZeneca supply

Australia on Monday approved the Pfizer-BioNTech COVID-19 vaccine for use but warned AstraZeneca's international production problems mean the country would need to distribute a locally manufactured shot earlier than planned.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Vaccination of priority groups with the Pfizer vaccine is expected to begin in late February, at 80,000 doses per week, Health Minister Greg Hunt told reporters.

The Australian rollout update comes after AstraZeneca Plc told European Union officials on Friday it would cut deliveries of its vaccine to the bloc by 60% in the first quarter due to production problems. Australia will start CSL's domestic supply of the AstraZeneca vaccine in March, earlier than planned, at 1 million doses a week, Hunt said. administration fights for $1.9 trillion relief plan

Officials in U.S. President Joe Biden's administration tried to head off Republican concerns that his $1.9 trillion pandemic relief proposal was too expensive on a Sunday call with Republican and Democratic lawmakers, some of whom pushed for a smaller plan targeting vaccine distribution.

While Congress has already authorized $4 trillion to respond, the White House says the additional $1.9 trillion is needed to cover the costs of responding to the virus and provide enhanced jobless benefits and payments to households. Trump administration lagged far behind its target of 20 million Americans inoculated by the end of 2020 and left no plan for how to distribute the vaccine to millions of Americans, White House Chief of Staff Ron Klain said on Sunday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.